Johnson and Johnson has posted stronger than expected Q3 results, helped by it riding out biosimilar challenges and strong growth from Stelara and a host of cancer drugs.
Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
